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Abstract: Background Severe acute respiratory syndrome – coronavirus-2 (SARS-CoV-2) has caused a
pandemic threatening the life of people with chronic respiratory diseases including cystic fibrosis (CF).
This study was designed to investigate health-related aspects of individuals with CF, with and without
lung transplantation (LTX), their communication with their specialist healthcare providers during the
pandemic, potential changes in peoples’ individual therapy regimes and daily physical activity levels.
Methods A web-based survey was conducted among Swiss adults with CF with and without LTX, study
period from March 16th, 2020 – the day the “extraordinary situation” was officially declared in Switzer-
land introducing stringent measures protecting the public – until May 16th, 2020. Results 327 individuals
(25% LTX recipients) were included, 45 individuals reported coronavirus-2019 disease (COVID-19) like
symptoms. Of 28 subjects tested, only three subjects were tested positive, all with mild symptoms, no
hospitalization required. Almost half of the survey respondents (45%) reported undertaking less physical
activity during the lockdown, while 79% and 91% of participants reported no change in traditional airway
clearance and inhalation therapies, respectively. Distress regarding a potential SARS-CoV-2 infection or
worsening of lung disease were no major concerns for subjects. Conclusions Our study reveals that the
direct impact of SARS-CoV-2 on clinical outcomes of individuals with CF was mild although people with
chronic lung diseases like CF are considered a high-risk population; overall, this is reassuring. However,
strict lockdown measures substantially affected peoples’ physical activity levels, a vital cornerstone of CF
therapy; and this is worrisome.
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a b s t r a c t 
Background: Severe acute respiratory syndrome – coronavirus-2 (SARS-CoV-2) has caused a pandemic 
threatening the life of people with chronic respiratory diseases including cystic fibrosis (CF). This study 
was designed to investigate health-related aspects of individuals with CF, with and without lung trans- 
plantation (LTX), their communication with their specialist healthcare providers during the pandemic, 
potential changes in peoples’ individual therapy regimes and daily physical activity levels. 
Methods: A web-based survey was conducted among Swiss adults with CF with and without LTX, study 
period from March 16th, 2020 – the day the “extraordinary situation” was officially declared in Switzer- 
land introducing stringent measures protecting the public – until May 16 th , 2020. 
Results: 327 individuals (25% LTX recipients) were included, 45 individuals reported coronavirus-2019 
disease (COVID-19) like symptoms. Of 28 subjects tested, only three subjects were tested positive, all 
with mild symptoms, no hospitalization required. Almost half of the survey respondents (45%) reported 
undertaking less physical activity during the lockdown, while 79% and 91% of participants reported no 
change in traditional airway clearance and inhalation therapies, respectively. Distress regarding a potential 
SARS-CoV-2 infection or worsening of lung disease were no major concerns for subjects. 
Conclusions: Our study reveals that the direct impact of SARS-CoV-2 on clinical outcomes of individuals 
with CF was mild although people with chronic lung diseases like CF are considered a high-risk popula- 
tion; overall, this is reassuring. However, strict lockdown measures substantially affected peoples’ physical 
activity levels, a vital cornerstone of CF therapy; and this is worrisome. 
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
Severe acute respiratory syndrome – coronavirus-2 (SARS-CoV- 
2), has caused a pandemic of unknown example to date [1] . The 
World Health Organization described the disease caused by SARS- 
CoV-2 coronavirus disease 2019 (COVID-19) [2] . The COVID-19 pan- 
demic impacted in health care systems worldwide, its long-term 
consequences are still to be seen. To date, predictors for the devel- 
opment of severe COVID-19 have not been well established; how- 
ever, patients with chronic lung diseases among other risk fac- 
tors are more likely to suffer [3] . When COVID-19 expanded from 
∗ Corresponding author at: Swisstransplant, Effingerstrasse 1, CH-3011 Berne 
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China to Europe and North America, it was unknown how COVID- 
19 affects people with cystic fibrosis (CF) lung disease given the 
much higher prevalence of CF as an inherited disease in the Cau- 
casian population within Europe and North America [4] . According 
to the latest European Cystic Fibrosis Society (ECFS) Patient Reg- 
istry Report, almost 50’0 0 0 individuals with CF live in 35 Euro- 
pean countries [5] . Further, CF is nowadays the second most com- 
mon primary indication for bilateral lung transplantation (LTX) in 
adults and the third most common overall indication based on fig- 
ures of a International Society for Heart and Lung Transplantation 
(ISHLT) Thoracic Transplant Registry Report [ 6 , 7 ]. To date, there is 
a paucity of data on predilection, presentation, and prognosis of 
COVID-19 after organ transplantation [8] . It is unknown, if post- 
transplant immunosuppression modifies the vulnerability of solid 
https://doi.org/10.1016/j.jcf.2020.08.013 
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organ transplant (SOT) recipients of acquiring SARS-CoV-2 or im- 
pacts considerably on the clinical course of COVID-19 [8] . 
Switzerland is one of the countries with the highest num- 
ber of COVID-19 cases per capita [9] . However, the COVID-19 
pandemic developed with regional differences, severely affecting 
French-speaking parts of Switzerland bordering with France, and 
the Italian-speaking Canton of Ticino bordering with Italy. In the 
French-speaking Canton of Geneva, there were more than 100 con- 
firmed cases per 10’0 0 0 inhabitants, in the Canton of Ticino more 
than 90 cases per 10’0 0 0 inhabitants [10] . Tschopp and co-workers 
have reported on the Swiss experience of SARS-CoV-2 infections in 
SOT recipients, describing 21 patients, predominately after abdom- 
inal organ transplantation but only one LTX recipient [11] . Overall, 
the clinical course of COVID-19 in SOT recipients seemed compara- 
ble to the general population; however, there was a selection bias 
towards symptomatic patients as SOT recipients with fewer or no 
symptoms were more likely not to report to a health care profes- 
sional for testing [11] . 
As there is a lack of data on the impact of SARS-CoV-2 on in- 
dividuals with CF with and without LTX during the COVID-19 pan- 
demic, we surveyed over 500 adults with CF living in Switzerland 
according to the ECFS Patient Registry, investigating medical and 
non-medical aspects related to the COVID-19 pandemic. We also 
aimed to capture the influence of SARS-CoV-2 on patients’ individ- 
ual therapy regimes, perceived health status and daily physical ac- 
tivity levels. We hypothesized that the effect on the health of peo- 
ple with CF with and without LTX is rather limited, with a larger 
burden on individuals’ overall health status and physical activity 
behaviour. 
2. Methods 
The Study Team, composed of a pulmonologist with special in- 
terest in CF and lung transplantation, an occupational medicine 
physician and an exercise scientist, developed a self-administered 
questionnaire with support of four individuals with CF. The ques- 
tionnaire (see supplementary material) contained questions on de- 
mographics and medical characteristics, current therapies, and in- 
dividuals’ perceptions towards various medical and non-medical 
aspects related to the SARS-CoV-2 crisis. In addition, the Study 
Team implemented a so-called “feeling thermometer”, a visual ana- 
logue scale (VAS) with marked intervals from 0 (worst imaginable 
health state) to 100 (best imaginable health state), part of the Eu- 
roQoL quality of life questionnaire (EQ-5D-5L) [12] . The EuroQoL is 
a valid health outcome instrument in CF [13] , previously applied in 
various LTX populations including people with CF [ 14 , 15 ]. 
Prior to starting the survey, the online questionnaire was pi- 
lot tested by four individuals with CF (two females) including one 
LTX recipient. The pilot was done to evaluate the comprehensibility 
of questions and instrument as a whole, and to estimate the time 
for completion the online survey. The individuals provided impor- 
tant feedback implemented into the survey. The final version of the 
questionnaire was made available in three national languages in 
Switzerland: French, German, and Italian. 
Severity of COVID-19 was classified using the following stages: 
Stage I — mild symptoms (e.g. dry cough, fatigue, headache); Stage 
II – moderate to severe symptoms (e.g., dyspnoea, hypoxia); Stage 
III – critical symptoms (e.g., acute respiratory distress syndrome, 
cardiac failure); Stage IV – death [16] . 
On April 27 th , 2020, one day after the first phase of easing the 
nationwide six-week complete lockdown during the pandemic in 
Switzerland, the online link to the questionnaire was distributed 
via email to all current members of the Swiss Cystic Fibrosis So- 
ciety, it was additionally also made available on the CFCH’ offi- 
cial Facebook page. A second survey invitation was sent as a re- 
minder on May 7 th , 2020. The Study Team additionally shared 
the link with the two Swiss LTX Centers, Centre Universitaire Ro- 
mand de Transplantation and the University Hospital Zurich, two 
Shared Care Centers in Basel and Berne caring for LTX patients, 
and the largest adult CF center in Switzerland, the Quartier Bleu in 
Berne. The questionnaire comprised the study period from March 
16th, 2020 – the day the Swiss Federal Office of Public Health de- 
clared the nationwide “extraordinary situation” introducing strin- 
gent measures to protect the public – until May 16th, 2020. 
The original study questionnaire was also translated into En- 
glish (see online supplements). 
This study does not fall under the scope of the Human Research 
Act. Research projects with anonymously collected or anonymous 
health-related personal data are exempt from requirement for 
approval. The study investigators paid special attention to the 
anonymity by using age categories and time of LTX (i.e., < 1 year, 
1–5 years, > 5 –10 years, > 10 years). 
2.1. Statistical methods 
Data were summarized as n (%) or median (interquartile range). 
Continuous outcomes were compared using the Wilcoxon-Mann- 
Whitney test (for two groups), or the Kruskal-Wallis test (for more 
than two groups), and categorical outcomes were compared using 
the chi-square test. Data cleaning and analysis was performed us- 
ing R (version 4.0), and graphs constructed using ggplot2 (version 
3.3) [ 17 , 18 ]. 
3. Results 
During the 3-week study period from 27 th , April 2020, 345 
survey responses were captured. Double-data entries were noted 
for three individuals, two respondents did not provide consent, 
nine responses were empty, and a further four were incomplete 
(only answered demographic questions), leaving 327 individual re- 
sponses for final analyses (270 questionnaires were completed in 
German, 47 in French and 10 in Italian). According to the latest 
report of the ECFS Patient Registry [5] , 517 adults with CF live in 
Switzerland, indicating that well over 50% of the Swiss adult CF 
population responded to the survey. 
3.1. Participant population 
Participants’ clinical and socioeconomic characteristics are 
shown in Table 1 and Table S1 , respectively. Among 327 respon- 
dents, 83 (25.4%) were LTX recipients, of which 14.6% reported to 
have chronic lung allograft dysfunction. In the LTX cohort, hyper- 
tension and diabetes were the most frequent co-morbidities. In the 
non-transplant cohort (n = 244, 48.4% females), about 85% of sub- 
jects reported to have known mild-to moderate CF lung disease, 
CF-related diabetes was the most frequent co-morbidity ( Table 1 ). 
Self-reported health status (EQ-5D VAS) of people with and with- 
out LTX is provided in Figure S1 . People without LTX reported 
a lower health status compared to those with LTX ( p = 0.002) 
( Figure S1 ). 
3.2. COVID-19 related symptoms, diagnostic testing and disease 
stages 
Between March 16 th to May 16 th 2020, 45 individuals (13.8%) 
conveyed to experience COVID-19 like symptoms ( Table 2 ). Among 
symptomatic subjects, 28 individuals underwent SARS-CoV-2 test- 
ing, three individuals (10.7%) were tested positive, all suffered with 
mild symptoms only - corresponding to COVID-19 Stage I, [16] indi- 
viduals self-quarantined, no hospitalization required. 
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Table 1 
Participants’ characteristics. 
Variables All Non-LTX LTX 
( n = 327) ( n = 244) ( n = 83) 
Sex 
Male 171 (52.3) 125 (51.2) 46 (55.4) 
Female 155 (47.4) 118 (48.4) 37 (44.6) 
Other 1 (0.3) 1 (0.4) –
Age categories 
< 40 years 237 (72.5) 192 (78.7) 45 (54.2) 
≥ 40 years 90 (27.5) 52 (21.3) 38 (45.8) 
Lung function (FEV 1 ) 
∗
> 80 % pred 64 (26.2) 64 (26.2) –
40 – 80 % pred 143 (58.6) 143 (58.6) –
< 40 % pred 37 (15.2) 37 (15.2) –
Years post LTX 
< 1 year 2 (2.4) – 2 (2.4) 
1–5 years 17 (20.5) – 17 (20.5) 
> 5 –10 years 30 (36.1) – 30 (36.1) 
> 10 years 34 (41.0) – 34 (41.0) 
Comorbidities 
Heart disease 3 (0.9) 2 (0.8) 1 (1.2) 
Hypertension 48 (14.7) 10 (4.1) 38 (45.8) 
Diabetes 135 (41.3) 69 (28.3) 66 (79.5) 
Kidney disease/-transplant 21 (6.4) 2 (0.8) 19 (22.9) 
Cancer # 7 (2.1) 3 (1.2) 4 (4.8) 
Data are presented as numbers (percent). FEV 1 , forced expiratory volume in 
1s; LTX, lung transplantation. 
∗ Lung function was only surveyed in non-transplant patients. 
# Other than skin cancer. 
Table 2 
COVID-19 like symptoms, diagnostic testing and disease stages. 
Variables All Non-LTX LTX 
( n = 327) ( n = 244) ( n = 83) 
COVID-19 like symptoms 45 (13.8) 38 (15.6) 7 (8.4) 
Symptomatic tested 28 (62.2) 21 (55.3) 7 (100) 
SARS-CoV-2 positive 3 (10.7) 2 (9.5) 1 (14.3) 
COVID-19 Stage I ∗ 3 (100) 2 (100) 1 (100) 
COVID-19 Stage II ∗ – – –
COVID-19 Stage III ∗ – – –
Asymptomatic tested 43 (13.1) 13 (5.3) 30 (36.1) 
Data are presented as numbers (percent). COVID-19, coronavirus dis- 
ease 2019; SARS-CoV-2, Severe Acute Respiratory Syndrome Coron- 
avirus 2. 
∗ COVID-19 stages were adapted from Sidiqqi & Mehra. 18 
3.3. Impact of the SARS-CoV-2 pandemic on patients’ daily 
maintenance therapy 
Table 3 provides an overview on changes in people’s daily 
maintenance therapy, i.e., physical activity, airway clearance, and 
inhalation therapy, a cornerstone of CF care. During lockdown, 
about 45%, 9%, and 2% of individuals undertook less daily PA, air- 
way clearance, and inhalation therapy, respectively ( Table 3 ). 
3.4. Physical activity 
Among those who reported to do less physical activity dur- 
ing the pandemic, reasons provided were closed training facilities 
(66%), lack of motivation (32%) or everyday structure (30%), and 
cancelled supervised training (27%), such as professional training 
therapy. Some survey respondents reported on self-organized in- 
formal virtual exercise groups via the video communication tool 
Zoom®, meeting twice daily for exercises such as Pilates®, gym- 
nastics, or yoga. 
3.5. Airway clearance and inhalation therapy 
Among non-transplant individuals 12% and 7% reported to per- 
form airway clearance and inhalation therapy more frequently dur- 
Table 3 
Impact of the SARS-CoV-2 pandemic on subjects’ daily 
maintenance therapy. 
Variables All Non-LTX 
Daily physical activity 
Total subjects 326 244 
No change in therapy 105 (32.2) 72 (29.5) 
Less frequently 146 (44.8) 110 (45.1) 
More frequently 75 (23.0) 62 (25.4) 
Daily airway clearance 
Total subjects 255 223 
No change in therapy 202 (79.2) 171 (76.7) 
Less frequently 22 (8.6) 22 (9.9) 
More frequently 31 (12.2) 30 (13.5) 
Daily inhalation therapy 
Total subjects 298 241 
No change in therapy 271 (90.9) 215 (89.2) 
Less frequently 6 (2.0) 5 (2.1) 
More frequently 21 (7.0) 21 (8.1) 
Data are presented as numbers (percent). 
ing the pandemic ( Table 3 ). Among those carrying out less therapy 
during lockdown, the most frequently reported single reason (55%) 
was canceled supervised therapy (i.e., physiotherapy, Table 3 ) and 
lack of motivation and nonexistent daily structure. 
3.6. Impact of COVID-19 lock-down on routine outpatient clinic 
appointments 
During the lockdown, 214 (66%) of subjects reported planned 
routine outpatient clinic appointments at their CF or transplant 
centers. Around half of appointments were either postponed or 
cancelled ( Table S2 ). Overall, routine clinic appointments were 
equally cancelled by either the specialist health care teams or the 
patients (51% vs. 49%). Among subgroups, patient-initiated cancel- 
lations of routine appointments were more frequently in LTX recip- 
ients compared to non-transplant individuals (64% vs. 44%). Alter- 
natives for cancelled or postponed appointments were provided by 
53% of specialist health care teams, telephone consultations were 
used most frequently (38%, see Table S2 ). During the study pe- 
riod, 173 (53%) individuals reported that their specialist health care 
team informed them directly about COVID-19 rules of conduct. In 
this regard, significant differences were noted between LTX recip- 
ients and non-transplant patients (83% vs. 43%, p < 0.0 0 01). Infor- 
mation were most commonly provided by e-mail (40%), less fre- 
quently by phone (16%) or other platforms (9%). Overall, 87% of 
survey respondents felt sufficiently well informed by their special- 
ist health care team. 
3.7. Impact of COVID-19 lockdown on patient’s health status 
Subjects reported not being concerned of an infection with 
coronavirus; however – among non-transplant individuals – peo- 
ple with advanced CF lung disease expressed the highest level of 
concern/fear of worsening lung disease ( Figure S2 ). 
4. Discussion 
This survey was designed to capture medical and non-medical 
aspects related to the COVID-19 pandemic in Swiss people with CF 
with and without LTX. In addition, we wanted to learn how in- 
dividuals with CF communicate with their specialist health care 
providers during the pandemic. Further, we aimed to explore the 
impact of SARS-CoV-2 on subjects’ individual therapy regimes and 
daily physical activity levels, as well as the socioeconomic impact 
of the pandemic on individuals with CF. 
Our study reveals that the impact of SARS-CoV-2 on Swiss indi- 
viduals with CF with and without LTX was interestingly only mild 
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despite the fact that people with chronic lung diseases are consid- 
ered a high-risk population. This is all the more surprising know- 
ing that Switzerland is one of the countries worldwide with the 
highest number of COVID-19 cases per capita [9] . Further, one- 
quarter of our study population were LTX recipients. So far, there 
is no robust data on the incidence of SARS-CoV-2/COVID-19 in LTX 
recipients, and their clinical presentation, clinical course, and over- 
all clinical outcome [8] . It remains to be seen, if immunosuppres- 
sion alters the likelihood of LTX recipients to capture a SARS-CoV-2 
infection or how immunosuppression changes the clinical course of 
COVID-19 in LTX recipients [8] . In our cohort, only 15% of patients 
reported COVID-19 like symptoms with 28 individuals undergo- 
ing diagnostic testing to exclude SARS-CoV-2. In total, only three 
subjects tested positive, all with mild symptoms - corresponding 
to COVID-19 Stage I [16] . No patient required hospital admission, 
all self-quarantined at home and recovered without sequelae. One 
of the three SARS-CoV-2 positive was a LTX patients. Our data 
complement the results of a very recently published multinational 
report from national CF registries in eight countries including a 
heterogenous patient group (n = 40), including eleven LTX recipi- 
ents. However, the method of case capture used in the study by 
Cosgriff et al. [19] was not exhaustive, thus, not identifying all 
cases. 
It is important to note that well less than 20% of the LTX sub- 
jects in our study cohort suffered with chronic lung allograft dys- 
function even though 77% of these individuals were over five years 
post-transplant. According to ISHLT Registry figures, over 50% of 
alive patients experience chronic lung allograft dysfunction five 
years post-transplant [7] . A low incidence of SARS-CoV-2 infections 
comparable to the general population was also reported in a large 
cohort of SOT recipients in Switzerland; however, the study cohort 
comprised almost exclusively abdominal transplant recipients [11] . 
Insufficient physical activity is a growing public health issue 
[20] , and a known major risk factor for cardiovascular disease 
and mortality [21] . In CF, physical activity is associated with aer- 
obic exercise capacity [22] , an independent predictor of mortality 
[23] . The pandemic and officially recommended protective mea- 
sures (i.e. social distancing and isolation policies for risk groups) 
impacted profoundly on survey respondents’ physical activity be- 
havior with almost half of the subjects reporting less physical ac- 
tivity during lockdown. Similar numbers where recently reported 
in a large population-based French survey, indicating that about 
52% of survey respondents performed less physical activity during 
lockdown [24] . Regular physical activity is a well-established cor- 
nerstone of maintenance CF care [ 25 , 26 ], and lack of physical activ- 
ity and increased sedentary behaviors potentially lead to deleteri- 
ous consequences regarding individuals’ overall health status. This 
is supported by a recent international survey showing that indi- 
viduals who reported a negative change in physical activity during 
early COVID-19-related restrictions stated lower mental and phys- 
ical health compared to their more active counterparts [27] . It is 
well described that many individuals with CF value physical ac- 
tivity as important for their (lung) health, overall well-being, and 
daily life [28] . Moreover, many people with CF incorporate physical 
activity and exercise into their airway clearance regimen and – ac- 
cording to recent surveys among individuals within the CF commu- 
nity – almost half of individuals have used exercise as substitute 
for traditional airway clearance techniques [ 29 , 30 ]. Given the fact 
that gym facilities and physiotherapy centers were closed during 
lockdown, it appears that some individuals “replaced” their phys- 
ical activity by increased airway clearance therapy. Further, some 
people with CF self-organised daily virtual exercise sessions among 
peers during the pandemic. 
Interestingly, the strict lockdown measures did not appear to 
impact on LTX recipients perceived health status [i.e., feeling ther- 
mometer (EQ-5D VAS, Figure S1 )]. The reported health status of 
LTX recipients during lockdown is perfectly comparable to a pre- 
viously conducted survey in Swiss LTX recipients [28] . The study 
including 111 adult LTX recipients with comparable clinical profile 
(i.e., 18% chronic lung allograft dysfunction) and gender distribu- 
tion showed a similar perceived health status as assessed with the 
EQ-5D VAS [28] . This is supported by the fact that – on a popula- 
tion level – LTX recipients with CF do not fear SARS-CoV-2 infec- 
tion or worsening of their lung disease ( Figure S2 ). 
A strength of our study is the high response rate in comparison 
to previously published web-based surveys in people with CF [31] . 
According to the latest ECFS Patient Registry Report [5] , 517 adults 
with CF live in Switzerland, 327 individuals from various regions 
across Switzerland participated in our study. 
This study has limitations due to its nature of a questionnaire- 
based survey; the accuracy of individual responses cannot be ver- 
ified possibly introducing self-reporting bias. However, as our sur- 
vey focused on a relatively short time period, i.e., from May 16 th , 
2020, the start of lockdown, until May 16 th , 2020, the ease of the 
lockdown, recall bias is unlikely to be a key problem in our survey. 
Moreover, our self-designed survey covered general demograph- 
ics and CF-related specific date (i.e., co-morbidities, lung function) 
and focused on participants’ perceptions and (potential) changes in 
therapy during the pandemic rather than sensitive information on 
health behaviors (i.e., drug use), all well known to be affected by 
social desirability bias. In this survey, physical activity was only as- 
sessed with a categorical variable (i.e., less, more, or unchanged) 
and not with a validated instrument. The study team was pri- 
marily interested in the subject’s overall perception of changes in 
physical activity during lockdown restrictions rather than provid- 
ing estimates of the time spent in different physical activity in- 
tensity domains and/or activity-related metabolic equivalents. Fi- 
nally, Switzerland has four official languages (German, French, Ital- 
ian, and Romansh) ; however, our survey was not provided in Ro- 
mansh as it is spoken by less than 1% of the total Swiss population, 
and most of those individuals also speak one of the other official 
languages. 
In summary, this study reveals that the direct impact of SARS- 
CoV-2 on clinical outcomes of individuals with CF was mild al- 
though people with chronic lung diseases such as CF are consid- 
ered a high-risk population, in particular, following LTX; overall, 
this is reassuring and a central message for CF and transplant com- 
munities alike. However, it warrants further research to evaluate if 
self-implementation of strict lockdown rules plays a key role here 
or if the subpopulation of individuals with CF with and without 
LTX is less vulnerable as thought earlier. This is even more so im- 
portant as individuals with CF in our study were more distressed 
by strict lockdown measures impacting on their daily lives, in par- 
ticular, their physical activity levels, a vital cornerstone of CF ther- 
apy; and this is worrisome. 
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